USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Grace Bio-oncology Laboratoryo
Address:
900 Auburn Road, Suite 105
Pontiac, MI 48342
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
Yes
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $349,999.00 6
SBIR Phase II $1,714,643.00 3

Award List:

ONCOGENE MARKERS AND CANCER RISK IN BENIGN BREAST CANCER

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
This research will develop an assay to predict which patients are at high risk to develop invasive cancer at the time of biopsy-proven benign breast disease. the approach will quantitate cells in benign breast disease tissue that have acquired autonomous phenotypes with respect to hormones and… More

A PROBE-CLIP DEVICE FOR IN SITU ASSAY OF BIOLOGICAL MOLECULES

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Charles M Mcgrath
Abstract:
N/a

FREEZE-TRANSFER METHOD FOR IN SITU DETECTION OF RNA

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$49,999.00
Agency:
HHS
Principal Investigator:
Charles M Mcgrath
Abstract:
N/a

FREEZE-TRANSFER METHOD FOR IN SITU DETECTION OF RNA

Award Year / Program / Phase:
1991 / SBIR / Phase II
Award Amount:
$485,032.00
Agency:
HHS
Principal Investigator:
Charles M Mcgrath
Abstract:
The objective is to develop a rapid and sensitive assay for in situ detection of receptor and related c-onc mrna in breast cancer. in situ is the method of choice because modest changes in per cell content of several key growth factor receptors can lead to selection and eventual domination of… More

A PROBE-CLIP DEVICE FOR IN SITU ASSAY OF BIOLOGICAL MOLECULES

Award Year / Program / Phase:
1992 / SBIR / Phase II
Award Amount:
$479,611.00
Agency:
HHS
Principal Investigator:
Charles M Mcgrath
Abstract:
The objective is to develop new in situ (hybridization and immunocytochemistry) assay technology to take full advantageof the new generation of reagents for detecting low-abundance regulatory macromolecules in cells. in situ assays often defer to biochemical assays even though they are better… More

Method to Preserve Labile Cytochemical Targets

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Charles M. McGrath
Abstract:
We will develop a new technology to address the need for a routine clinical method to preserve tissue for cytochemical assay. The new technology addresses the fact that frozen specimens are preferred for bioactivity, but available methods give inaccurate data. The method LYOPHILM combines… More

Specimen Preparation for In Situ PCR

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$75,000.00
Agency:
HHS
Principal Investigator:
Charles Mc Grath
Abstract:
Our objective is to increase the sensitivity of in situ PCR , by improving methods of specimenpreparation. We have devised a LYOPHILM technology, which comprises lyophilization of specimen onspecialized microporous nitrocellulose films, to allow reactants to thoroughly penetrate specimen tomaximize… More

Perfusion Devices for Cell Analysis

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$75,000.00
Agency:
HHS
Principal Investigator:
Charles Mc Grath
Abstract:
N/a

Perfusion Devices for Cell Analysis

Award Year / Program / Phase:
1996 / SBIR / Phase II
Award Amount:
$750,000.00
Agency:
HHS
Principal Investigator:
Charles Mc Grath
Abstract:
The plan is to test the hypothesis that sufficient porosity can be created in thin tissue sectionsto move reactants dynamic perfusion. This is expected to require control of the freezing rate inlyophilization and use of proprietary microporous film technology. At present, reagents are introducedin… More